REP 2139-Ca

REP 2139-Ca · Replicor Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for REP 2139-Ca, covering 2017-09-28 to 2019-05-08. Get the full timeline:

Most recent: Clinical Trial Update: Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B [Phase 2]